Clinical Trial Update: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of pembrolizumab (MK-3475) combination therapies for metastatic castration-resistant prostate cancer (MK-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING